About Accellix
Accellix is a company based in San Jose (United States) founded in 2007. Accellix has raised $35.84 million across 10 funding rounds from investors including BioMerieux, Broadoak Capital Partners and Axcel. Accellix offers products and services including Accellix Platform, Instrument and Software, Standard Assay Kits, Custom Assay Kits, and Algorithm-Based Autoanalysis. Accellix operates in a competitive market with competitors including Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Accellix, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$35.84 M (USD)
in 10 rounds
-
Latest Funding Round
$10 M (USD), Series D
Dec 13, 2021
-
Investors
BioMerieux
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Accellix
Accellix offers a comprehensive portfolio of products and services, including Accellix Platform, Instrument and Software, Standard Assay Kits, Custom Assay Kits, and Algorithm-Based Autoanalysis.
Automated bench-top platform for flow cytometry in GMP manufacturing.
Software for configurable data analysis in cell therapy workflows.
Kits that automate sample preparation for accurate phenotyping.
Tailored assays for specific research and manufacturing needs.
Tools for fully automated data analysis and classification.
People of Accellix
Unlock access to complete
Funding Insights of Accellix
Accellix has successfully raised a total of $35.84M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series D — $10.0M
-
First Round
First Round
(13 Jul 2009)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series D - Accellix | Valuation | Broadoak Capital Partners |
|
| Jul, 2020 | Amount | Series D - Accellix | Valuation |
investors |
|
| Jun, 2020 | Amount | Series D - Accellix | Valuation | BioMerieux |
|
Investors in Accellix
Accellix has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include BioMerieux, Broadoak Capital Partners and Axcel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are offered in the United States.
|
Founded Year | Domain | Location | |
|
Developer of diagnostics devices for multiple health purposes
|
Founded Year | Domain | Location | |
|
Axcel is engaged in private equity investments for value creation.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Accellix
Financial Statements - Accellix
Accellix Comparisons
Competitors of Accellix
Accellix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Eclipse Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| domain | founded_year | HQ Location |
Provider of products and services for human protein biomarker research and development
|
|
| domain | founded_year | HQ Location |
An in vitro assay platform is provided for diagnostic solutions.
|
|
| domain | founded_year | HQ Location |
Cell-free immunoassays are developed to identify RNA binding protein targets.
|
|
| domain | founded_year | HQ Location |
Correlia Biosystems is focused on protein quantification technology.
|
Latest news on Accellix
Frequently Asked Questions about Accellix
Accellix was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Accellix is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Nir Nimrodi is the current CEO of Accellix.
Accellix is a funded company, having raised a total of $35.84M across 10 funding rounds to date. The company's 1st funding round was a Series D of $9.5M, raised on Jul 13, 2009.
Accellix was founded in 2007 in San Jose, United States, within the biotechnology sector. Immunotherapy-based assay delivery platforms are developed, incorporating dry reagents and microfluidic cartridges. Bead assays, cell assays, and enzymatic PCR are provided as core offerings. Additional services include diluent processing, laser and optics integration, photon capture, electronics, and related components for assay applications.
Accellix's top competitors include Abingdon Health, Eclipse Bio and Spear Bio.
Accellix offers Accellix Platform, Instrument and Software, Standard Assay Kits, Custom Assay Kits, and Algorithm-Based Autoanalysis.
Accellix has 3 investors. Key investors include BioMerieux, Broadoak Capital Partners, and Axcel.